Effect of fluoxetine on organ dysfunction and mortality in severe sepsis.

ABSTRACT:

Introduction

Sepsis is a leading cause of morbidity and mortality in intensive care units, characterized by a dysregulated host response to infection. Recent evidence suggests fluoxetine, a selective serotonin reuptake inhibitor, may exert immunometabolic effects beneficial in sepsis. The aim of this study is to evaluate the effect of fluoxetine on vasopressor duration, organ dysfunction, inflammatory markers, and mortality in adult patients with severe sepsis.

Materials and methods

In this single-center, randomized, double-blind, placebo-controlled trial conducted at Ain Shams University Hospitals (December 2024-June 2025), 46 patients with severe sepsis were randomized 1:1 to receive either fluoxetine (40 mg/day) or placebo in addition to standard sepsis care. The primary

SUBMITTER: Taher IAA 

PROVIDER: S-EPMC12822927 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature